跨膜蛋白
整体膜蛋白
膜蛋白
跨膜结构域
重组DNA
细胞生物学
融合蛋白
蛋白质工程
化学
生物
生物化学
基因
膜
受体
酶
作者
Yao Wang,Shaoting Weng,Yajie Tang,Lin Su,X. Shirley Liu,Wenhui Zhang,Gang Liu,Pandi Boomi,Yinrong Wu,Li Ma,Lin Wei
标识
DOI:10.1016/j.pep.2023.106392
摘要
Cluster of differentiation 20 (CD20) is a nonglycosylated, multispanning transmembrane protein specifically integrated by B lymphocytes. Similar to CD20, another four-pass transmembrane protein, claudin 18.2, has attracted attention as an emerging therapeutic target for cancer. However, their poor solubility and toxic nature often hinder downstream applications, such as antibody drug development. Therefore, developing a cost-effective method for producing drug targets with multiple membrane-spanning domains is crucial. In this study, a high yield of recombinant CD20 was achieved through an E. coli–based in vitro coupled transcription–translation system. Surface plasmon resonance results showed that rituximab (an antileukemia drug) has nanomolar affinity with the CD20 protein, which aligns with published results. Notably, a previously hard-to-express claudin 18.2 recombinant protein was successfully expressed in the same reaction system by replacing its membrane-spanning domains with the transmembrane domains of CD20. The folding of the extracellular domain of the chimeric protein was verified using a commercial anti-claudin 18 antibody. This study provides a novel concept for promoting the expression of four-pass transmembrane proteins and lays the foundation for the large-scale industrial production of membrane-associated drug targets, similar to claudin 18.2.
科研通智能强力驱动
Strongly Powered by AbleSci AI